A plain-language look at what the big GLP-1 weight-loss trials actually found, why the numbers vary so much, and why lifestyle still does real work.
Start with the numbers, not the noise
GLP-1 medication has been studied in large, well-run trials with thousands of participants. That research is the reason doctors take this class of treatment seriously. It is also why responsible clinics avoid big promises.
Across the main trials, average weight loss ranged from roughly 8% of body weight to over 20%, depending on the specific medication and the dose reached. On a person weighing 100 kg, that is somewhere between about 8 kg and more than 20 kg on average. Averages hide a wide spread. Some people lost a great deal more, and some lost very little.
What "average" really means
An average is a single number standing in for a crowd. In these trials the crowd was mixed. A minority saw dramatic change. A minority saw modest change. Most sat somewhere in the middle. When you read a headline figure, picture that range rather than a guarantee for one person.
Why results vary so much
No two bodies respond the same way, and the trials show it. A few things shaped the outcome for each participant:
- The medication and dose. Higher-strength options and higher doses generally produced larger average losses in the studies.
- How long treatment continued. Weight tended to come down gradually over months, not in the first few weeks.
- Starting point and health history. Age, sex, metabolism and existing conditions all play a part.
- What happened alongside the injection. Trials paired the medication with dietary and activity support. The medication was never tested on its own.
Results vary. That is not a disclaimer bolted on at the end. It is one of the clearest findings in the data.
How the medication actually helps
These medicines act like a gut hormone your body already makes. They work on appetite, slowing how quickly the stomach empties and turning down the constant background pull toward food that many people call "food noise". People in the trials tended to feel satisfied sooner and think about eating less often.
That is a real mechanism, not willpower in a syringe. It makes eating less feel achievable rather than effortless.
Lifestyle still does real work
The trials did not test a pill against a plate of chips. They tested medication plus support against a dummy injection plus the same support. The medication group did far better, which is the point. But the shared groundwork mattered.
Eating enough protein, staying active and protecting sleep help you lose fat rather than muscle, and they help you hold onto progress. The studies also point to a hard truth: when people stopped treatment, a meaningful share of the weight tended to return over time. That suggests obesity behaves like a long-term condition, and that the habits built alongside treatment are part of what keeps results.
Side effects were common but usually manageable
Nausea, and changes to digestion were the most reported effects in the trials, most often early on and often easing as the dose was raised slowly. A smaller number of people stopped because of side effects. This is one reason treatment in South Africa is doctor-led, using SAHPRA-registered medicines and a gradual dose that an HPCSA-registered doctor adjusts to how you respond.
Reading trial results like a sceptic
A few habits will keep your expectations grounded:
- Treat any single percentage as the middle of a range, not a target.
- Ask which medication, which dose and how many months produced a figure.
- Remember that trial participants had structured support most of us have to organise for ourselves.
The evidence is genuinely encouraging. It is also specific, and it rewards patience over hype.
Where this leaves you
This is general information and not medical advice. A registered doctor decides what suits an individual after reviewing your health, your history and your goals.
As a rough guide, treatment is usually considered from a BMI of 30 and up, or 27 and up alongside a weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea or fatty liver. It is not suitable during pregnancy or breastfeeding, or with a personal or family history of medullary thyroid cancer or MEN 2. If you are curious whether this fits your situation, a short conversation with one of our doctors is a sensible next step.
The short version
- Average weight loss in the trials ran from about 8% to over 20% of body weight, depending on medication and dose.
- An average is a range, not a promise. Some people lost far more, some far less.
- The medication works on appetite and food noise, but it was always tested alongside diet and activity support.
- Weight tended to return after stopping, which is why habits and ongoing, doctor-led care matter.
See if this could be an option for you
A two-minute eligibility check, reviewed by a doctor registered with the HPCSA. No obligation, and you only pay if a doctor decides treatment is right for you.
Check if you qualifyWondering if this applies to you?
The eligibility check is free and takes about two minutes.
This article is general information, not medical advice, and it cannot take the place of a consultation. GLP-1 medicines require assessment by a doctor registered with the HPCSA. Speak to a doctor about your own circumstances. See our medical disclaimer and editorial policy.